Healthcare

● Armata Pharmaceuticals shares have fallen sharply, most recently closing at $4.42, down 12.82%, after reporting Q2 2026Net Incomeof about $74.1 million, driven primarily by a roughly $91.0 million non-cash gain from a change in theFair Valueof its convertible loan.

● BioAge Labs shares have fallen sharply, most recently closing at $9.69, down 9.86%, with no specific single catalyst identified, extending a drawdown that one data provider characterized as roughly two-thirds off its post-IPO highs.

● Autonomix Medical shares have fallen sharply, most recently closing at $5.27, down 10.83%, following a 1-for-21 reverse split effective June 24, 2026.

● Aardvark Therapeutics shares have fallen sharply, most recently closing at $5.89, down 12.74%, near the bottom of a 52-week range of about $3.35 to $17.94.

● Agenus shares have fallen sharply, most recently closing at $7.49, down 9.32%, after a rally that had taken the stock sharply higher off its 52-week low.

With this increase, it is on the brink of becoming a Dividend King, having consistently raised its dividend for 49 consecutive years. This milestone underlines not only Medtronic (NYSE: MDT)’s commitment to returning value to shareholders but also positions it favorably among income-focused investors …

Novo Nordisk is testing lower doses of its obesity treatment Wegovy, aiming to identify the most effective dosing that also reduces costs and side effects. This study underscores the growingDemandfor weight loss solutions that patients can afford and tolerate, appealing to investors focused on …